BioMark Diagnostics Inc.
BUX
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.90K | 111.00K | 110.80K | 113.10K | 116.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.90K | 111.00K | 110.80K | 113.10K | 116.10K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 87.90K | 111.00K | 110.80K | 113.10K | 116.10K |
| SG&A Expenses | 595.20K | 675.10K | 807.60K | 767.00K | 780.00K |
| Depreciation & Amortization | 335.30K | 315.10K | 284.70K | 201.40K | 232.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.33M | 1.43M | 1.58M | 1.51M | 1.61M |
| Operating Income | -1.24M | -1.32M | -1.47M | -1.40M | -1.50M |
| Income Before Tax | -1.18M | -1.24M | -1.39M | -1.39M | -1.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.18 | -1.24 | -1.39 | -1.39 | -1.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.18M | -1.24M | -1.39M | -1.39M | -1.45M |
| EBIT | -1.24M | -1.32M | -1.47M | -1.40M | -1.50M |
| EBITDA | -1.23M | -1.31M | -1.46M | -1.39M | -1.49M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.20B | 1.19B | 1.17B | 1.15B | 352.25M |
| Average Diluted Shares Outstanding | 1.20B | 1.19B | 1.17B | 1.15B | 352.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |